Not on my reading on their announcement
The bigger question is why did they need to transfer to a GMP facility to make these new doses?
Answer, because someone's regulations ( US Dept of defence for example, Indonesian trial requirement, expanded diabetic foot ulcer trials) require the product to be made to full GMP requirements.
Which means they are producing doses in higher amounts to fulfill expectations of requirements for one or more of these trials.
So it is a step in the right direction and a sign of momentum, that has been lacking until recently.
Not on my reading on their announcementThe bigger question is...
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.005(0.97%) |
Mkt cap ! $120.5M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.0¢ | 52.0¢ | $4.485K | 8.497K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.0¢ | 14897 | 2 |
View Market Depth
| Last trade - 15.47pm 04/10/2024 (20 minute delay) ? |
| RCE (ASX) Chart |